Basic Information
| LncRNA/CircRNA Name | FBXL19-AS1 |
| Synonyms | NA |
| Region | GRCh38_16:30919319-30923269 |
| Ensemble | ENSG00000260852 |
| Refseq | NR_024348 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP, etc. |
| Sample | Lung cancer tissues, Lung cancer cell lines (A549, H1975, SPC-A-1, H125, and H1299) and normal human lung cells (MRC-5) |
| Expression Pattern | up-regulated |
| Function Description | FBXL19-AS1 expression was up-regulated in lung cancer tissues and cell lines. FBXL19-AS1 knockdown inhibited cell proliferation, migration, invasion, and angiogenesis in lung cancer cells.Molecular mechanism exploration uncovered that FBXL19-AS1 acted as a molecular sponge of miR-431-5p and that RAF1 was a downstream target of miR-431-5p in lung cancer. Moreover, there was a negative association between miR-431-5p expression and FBXL19-AS1 or RAF1 expression in tumor tissues. Through rescue experiments, we discovered that overexpression of RAF1 partially rescued FBXL19-AS1 knockdown-mediated inhibition of angiogenesis and progression in lung cancer. Together, these results indicated that FBXL19-AS1 was involved in progression and angiogenesis in lung cancer by targetingmiR-431-5p/RAF1 axis, which provided a new insight into the therapeutic strategies of lung cancer. |
| Pubmed ID | 30610161 |
| Year | 2019 |
| Title | FBXL19-AS1 exerts oncogenic function by sponging miR-431-5p to regulate RAF1 expression in lung cancer |
External Links
| Links for FBXL19-AS1 | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |